CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that it is presenting preclinical data from a study evaluating the mechanism of action of one of its Toll-like receptor (TLR) 7 and TLR9 antagonist candidates in a model of hyperlipidemia. The presentation, entitled “Novel TLR7 and TLR9 Dual Antagonist Lowers Cholesterol in Hyperlipidemic Mice Through IL-10-Mediated Activation of LXR and Increased Fecal Neutral Sterol Loss” (abstract #7068), is being made in the “Inflammation and Adhesion” session at the American Heart Association Scientific Sessions 2010 Meeting in Chicago, IL.
